Skip to content

US · SGRY · MEDICAL - CARE FACILITIES

Surgery Partners, Inc. (SGRY) intrinsic value and stock valuation

$26.78as of 2026-11-21 · Mkt cap 2.03B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Surgery Partners, Inc. DCF and intrinsic value

InvestorsCraft values SGRY with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SGRY’s statements →

Surgery Partners, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Care Facilities Brentwood, TN 37027 surgerypartners.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$3.31B+12.2% 5y CAGRd
20122025
Net income
-$-77.9M
20122025
Free cash flow
$195.6M-0.8% 5y CAGRd
20122025
Total equity
$3.53B+16.8% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$3.31B$3.11B$2.74B$2.54B$2.23B
Operating income$389.5M$348.8M$328M$345.2M$302.2M
Net income-$-77.9M-$-168.1M-$-11.9M-$-54.6M-$-70.9M
EPSd-$-612.37K-$-1.33M-$-94.74K-$-593.8K-$-978.88K
Operating cash flow$274.3M$300.1M$293.8M$158.8M$87.1M
Capital expenditure-$-78.7M-$-90.4M-$-88.8M-$-80.6M-$-57.6M
Free cash flow$195.6M$209.7M$205M$78.2M$29.5M
Total assets$8.24B$7.89B$6.88B$6.68B$6.12B
Total debt$4.02B$3.7B$3.06B$2.93B$3.29B
Net debt$3.78B$3.43B$2.87B$2.65B$2.9B
Total equity$3.53B$3.64B$3.36B$3.28B$2.3B
Cash and short-term investments$239.9M$269.5M$195.9M$282.9M$389.9M
Income statement
20252024202320222021
Revenue$3.31B$3.11B$2.74B$2.54B$2.23B
Cost of revenue$2.54B$2.37B$2.1B$1.96B$1.73B
Gross profit$765M$745.6M$647.5M$574.9M$491.4M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$522.7M$138.7M$120.9M$102.2M$104M
Other expenses-$-147.2M$258.1M$198.6M$127.5M$85.2M
Operating expenses$375.5M$396.8M$319.5M$229.7M$189.2M
Cost and expenses$2.92B$2.77B$2.42B$2.19B$1.92B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$272.6M$201.7M$193M$234.9M$221M
Depreciation and amortization$176M$152.6M$118.1M$114.8M$98.8M
Ebitda$565.5M$501.4M$446.1M$460M$401M
Operating income$389.5M$348.8M$328M$345.2M$302.2M
Total other income/expenses, net-$-272.6M-$-201.7M-$-193M-$-234.9M-$-221M
Income before tax$116.9M$147.1M$135M$110.3M$81.2M
Income tax expense$18M$134.6M-$-300K$23.3M$10.5M
Net income-$-77.9M-$-168.1M-$-11.9M-$-54.6M-$-70.9M
Weighted average shares outstanding$127.2M$126.1M$125.6M$92M$72.4M
Weighted average diluted shares outstanding$127.2M$126.1M$125.6M$92M$72.4M
Balance sheet
20252024202320222021
Cash and short-term investments$239.9M$269.5M$195.9M$282.9M$389.9M
Net receivables$602.2M$579.1M$496.4M$456.3M$430.2M
Inventory$96.6M$88.4M$75.2M$71.4M$61.1M
Total current assets$1.15B$1.12B$895M$921M$946.1M
Property, plant and equipment, net$1.44B$1.38B$1.22B$1.16B$953.8M
Goodwill and intangible assets$5.24B$5.11B$4.38B$4.18B$3.96B
Long-term investments$234M$215.4M$184.1M$190.3M$88.7M
Total non-current assets$7.09B$6.77B$5.98B$5.76B$5.17B
Total assets$8.24B$7.89B$6.88B$6.68B$6.12B
Accounts payable$208.7M$208.7M$171.8M$151.6M$124.9M
Short-term debt$142M$142.4M$110.9M$99.3M$100.5M
Deferred revenue$0.00$0.00$0.00$3.2M$64.4M
Total current liabilities$615.5M$624.4M$523M$493.4M$536.8M
Long-term debt$3.88B$3.56B$2.95B$2.83B$3.19B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.1B$3.63B$2.99B$2.91B$3.28B
Capital lease obligations$1.22B$333.1M$286.5M$307.9M$355.7M
Total liabilities$4.72B$4.25B$3.51B$3.4B$3.82B
Common stock$1.3M$1.3M$1.3M$1.3M$900K
Retained earnings-$-815.2M-$-737.3M-$-569.2M-$-557.3M-$-502.7M
Accumulated other comprehensive income (loss)-$-13.8M$4.8M$57.5M$76.2M-$-31.5M
Total equity$3.53B$3.64B$3.36B$3.28B$2.3B
Total investments$234M$215.4M$184.1M$190.3M$88.7M
Total debt$4.02B$3.7B$3.06B$2.93B$3.29B
Net debt$3.78B$3.43B$2.87B$2.65B$2.9B
Cash flow statement
20252024202320222021
Net income$98.9M$12.5M$135.3M$87M$70.7M
Depreciation and amortization$176M$152.6M$118.1M$114.8M$98.8M
Stock-based compensation$14.8M$33.3M$17.7M$18.4M$17.4M
Change in working capital-$-110.4M-$-118.9M-$-62.3M-$-102.3M-$-149.1M
Accounts receivable-$-53.8M-$-72.1M-$-47.2M-$-35.3M-$-32.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$274.3M$300.1M$293.8M$158.8M$87.1M
Investments in property, plant and equipment-$-78.7M-$-90.4M-$-88.8M-$-80.6M-$-57.6M
Acquisitions, net-$-162.1M-$-378.8M-$-128.9M-$-228.7M-$-280.4M
Net cash used for investing activities-$-246.6M-$-488.5M-$-225.6M-$-307.9M-$-331.7M
Common stock issued$0.00$0.00$0.00$882.9M$581.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-5.1M
Net cash used for financing activities-$-57.3M$262M-$-155.2M$42.1M$316.3M
Net change in cash-$-29.6M$73.6M-$-87M-$-107M$71.7M
Cash at end of period$239.9M$269.5M$195.9M$282.9M$389.9M
Operating cash flow$274.3M$300.1M$293.8M$158.8M$87.1M
Capital expenditure-$-78.7M-$-90.4M-$-88.8M-$-80.6M-$-57.6M
Free cash flow$195.6M$209.7M$205M$78.2M$29.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Surgery Partners, Inc.

        Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.

        CEO
        J. Eric Evans
        Employees
        16K
        Beta
        1.89

        Explore

        Frequently asked questions

        What is the intrinsic value of Surgery Partners, Inc. (SGRY)?

        Surgery Partners, Inc. (SGRY) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SGRY undervalued?

        SGRY trades at a price of $26.78 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.